Monte Rosa Therapeutics (GLUE) Accounts Payables (2020 - 2026)

Monte Rosa Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 51.5% year-over-year to $7.9 million; the TTM figure through Mar 2026 stood at $7.9 million (down 51.5% YoY), while the FY2025 annual figure was $26.7 million, up 55.06% from the prior year.
• Accounts Payables was $7.9 million for Q1 2026 at Monte Rosa Therapeutics, down from $26.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $26.7 million in Q4 2025 to a low of $4.0 million in Q3 2024.
• Historically, Accounts Payables has averaged $11.1 million across 5 years, with a median of $9.8 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables surged 1463.4% in 2022, then sank 56.26% in 2025.
• A 5-year view of Accounts Payables shows it stood at $14.6 million in 2022, then advanced by 0.14% to $14.6 million in 2023, then rose by 17.91% to $17.2 million in 2024, then surged by 55.06% to $26.7 million in 2025, then plunged by 70.41% to $7.9 million in 2026.
• The last three Accounts Payables figures came in at $7.9 million (Q1 2026), $26.7 million (Q4 2025), and $17.9 million (Q3 2025), per Business Quant data.